# Eileen M. O'Reilly

Source: https://onco.cc/people/eileen-oreilly/  
OnCo record `eileen-oreilly` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leading pancreatic cancer trialist, including the maintenance PARP-inhibitor and germline-BRCA studies.

## Summary

Eileen M. O'Reilly holds the Winthrop Rockefeller Chair in Medical Oncology and is Section Head of Hepatopancreaticobiliary and Neuroendocrine Cancers at Memorial Sloan Kettering Cancer Center. She is a leading pancreatic cancer trialist, known for the maintenance PARP-inhibitor and germline BRCA studies in the disease. Her selected paper reports a randomised phase 2 trial of gemcitabine and cisplatin with or without veliparib in pancreatic adenocarcinoma with a germline BRCA or PALB2 mutation. She directs pancreatic and hepatobiliary cancer research at MSK and leads trials in BRCA-mutant pancreatic cancer and NCI cooperative group gastrointestinal studies.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Winthrop Rockefeller Chair in Medical Oncology; Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
- Specialisms: Pancreatic cancer; Biliary cancer; BRCA-associated pancreatic cancer

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=O'Reilly%20EM%5BAuthor%5D

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/), [Pancreatic acinar cell carcinoma](https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Lustgarten Foundation](https://onco.cc/institutions/lustgarten-foundation/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- key papers: [Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer](https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/), [Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial](https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/), [eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer](https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/), [Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection](https://onco.cc/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/), [Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations](https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/), [Metastatic Pancreatic Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/), [O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation](https://onco.cc/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/), [Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/), [Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms](https://onco.cc/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/), [RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer](https://onco.cc/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/), [Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion](https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/eileen-oreilly.json